Stephan Krähenbühl
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC
Schett A, Rothschild S, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Jörger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol 2019; 85:121-131.
19.11.2019Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC
19.11.2019Cancer Chemother Pharmacol 2019; 85:121-131
Schett Anne, Rothschild Sacha I, Curioni-Fontecedro Alessandra, Krähenbühl Stephan, Früh Martin, Schmid S, Driessen Christoph, Jörger Markus
Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
Hoemme A, Driessen C, Früh M, Thürlimann B, Wälti T, von Kameke A, Lehner C, Strasser F, Krähenbühl S, Haschke M, Barth H, Jörger M. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol 2019; 83:763-774.
25.01.2019Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer
25.01.2019Cancer Chemother Pharmacol 2019; 83:763-774
Hoemme Alexander, Driessen Christoph, Früh Martin, Thürlimann Beat, Wälti Thomas, von Kameke Alexander, Lehner Claudia, Strasser Florian, Krähenbühl Stephan, Haschke Manuel, Barth Holger, Jörger Markus
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
Parra-Guillen Z, Kloft C, Krähenbühl S, Gillessen Sommer S, Früh M, Pfister B, Winogradova D, Donzelli M, Haschke M, Berger P, Jörger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.
19.06.2017Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
19.06.2017Basic Clin Pharmacol Toxicol 2017; 121:309-315
Parra-Guillen Zinnia P, Kloft Charlotte, Krähenbühl Stephan, Gillessen Sommer Silke, Früh Martin, Pfister Bogumila, Winogradova Daria, Donzelli Massimiliano, Haschke Manuel, Berger Peter B, Jörger Markus
Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon
Caduff Good A, Nobel D, Krähenbühl S, Geisen C, Henz S. Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon. Swiss Med Wkly 2013; 143:w13709.
08.01.2013Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon
08.01.2013Swiss Med Wkly 2013; 143:w13709
Caduff Good Angela, Nobel Daniel, Krähenbühl Stephan, Geisen Christof, Henz Samuel
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
Jörger M, Ferreri A, Krähenbühl S, Schellens J, Cerny T, Zucca E, Huitema A. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 2012; 73:240-7.
01.02.2012Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
01.02.2012Br J Clin Pharmacol 2012; 73:240-7
Jörger Markus, Ferreri Andrés J M, Krähenbühl Stephan, Schellens Jan H M, Cerny Thomas, Zucca Emanuele, Huitema Alwin D R
Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase
Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion 2006; 74:28-32.
19.09.2006Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase
19.09.2006Digestion 2006; 74:28-32
Bodmer Michael, Sulz Michael, Stadlmann Sylvia, Droll Armin, Terracciano Luigi, Krähenbühl Stephan
Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function
Egger S, Sawatzki M, Drewe J, Krähenbühl S. Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function. Pharmacotherapy 2005; 25:881-5.
01.06.2005Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function
01.06.2005Pharmacotherapy 2005; 25:881-5
Egger Sabin S, Sawatzki Mikael, Drewe Jürgen, Krähenbühl Stephan